AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23945372
Drug: Capsule size
RxNorm normalized name: Empty Capsule Size 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule size
Trial: 23945372
Drug: CSF capsule
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF capsule shedding
Trial: 23947389
Drug: Switch antipsychotic
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch antipsychotic plus healthy lifestyle education (HLE)
Trial: 23947389
Drug: Add metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add metformin plus healthy lifestyle education (HLE)
Trial: 23947389
Drug: Healthy lifestyle
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy lifestyle education (HLE) with no medication change
Trial: 23948110
Drug: Drug eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug eluting balloon (DEB)
Trial: 23949214
Drug: 150 IU
RxNorm normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU HCG daily for 7 days
Trial: 23953882
Drug: Sequential arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential arm (starting on day 14)
Trial: 23953988
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (iv LCM) at a loading dose of 400 mg over 30 min, followed by a mean maintenance dose of 400 mg per day
Trial: 23953988
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (iv LCM)
Trial: 23954889
Drug: Pomalidomide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (2.5 mg/d), cyclophosphamide (50 mg every other day), prednisone (50 mg every other day) for 6 cycles, followed by maintenance therapy.
Trial: 27101285
Drug: Anti-angiogenic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenic therapy
Trial: 23961354
Drug: Department of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Department of Health pamphlet about breast cancer and treatment
Trial: 23963055
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of transdermal nicotine (mean NRT dose 32.7 mg/d; range, 7-56 mg/d)
Trial: 23963055
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of transdermal nicotine
Trial: 23965261
Drug: Motivational pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational pharmacotherapy
Trial: 23966428
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Ca + 400 IU vitamin D3/d (Calcium/Vitamin D Trial)
Trial: 23968316
Drug: Patient training
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
Trial: 23969187
Drug: Metreleptin (0.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.22 mg/kg/d) for 12 months
Trial: 23969187
Drug: Metreleptin treatment
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin treatment for 12 months
Trial: 23969281
Drug: Actions taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actions taken to relieve withdrawal symptoms (e.g., nicotine use)
Trial: 23969281
Drug: Withdrawal symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal symptoms (e.g., anxiety, cannabis craving)
Trial: 23970725
Drug: Mifepristone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone treatment
Trial: 23971740
Drug: Calcitriol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.75 mcg/day
Trial: 23971740
Drug: Calcitriol +
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol + Lisinopril
Trial: 23971740
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Lisinopril
Trial: 23973693
Drug: Highest HDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest HDL-C quintile among subjects with LDL-C <70 mg/dl
Trial: 23975665
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m² at week 1, then 250 mg/m²/week) and Gemcitabine (1 g/m² on day 1, 8 and 15 every 4 weeks)
Trial: 23976960
Drug: Trivalent surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent surface antigen, inactivated influenza vaccine (15 µg hemagglutinin of each virus strain)
Trial: 23976960
Drug: Trivalent surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent surface antigen, inactivated influenza vaccine
Trial: 23978163
Drug: CBMNC transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBMNC transplantation and rehabilitation therapy
Trial: 23978163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBMNC and UCMSC transplantation and rehabilitation therapy
Trial: 23978163
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rehabilitation therapy only)
Trial: 23978364
Drug: Newer agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer agents (prasugrel or ticagrelor)
Trial: 23979288
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification and medical therapy
Trial: 23979353
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy for 12 months
Trial: 23979733
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus Dolutegravir (DTG) 50 mg every 24 h for 5 days
Trial: 23979733
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus GSK1265744 30 mg every 24 h for 12 days
Trial: 23979733
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) 50 mg every 24 h for 5 days
Trial: 23979733
Drug: GSK1265744 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (30 mg every 24 h for 12 days)
Trial: 23980906
Drug: Betaine HCl
RxNorm normalized name: betaine HCl
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine HCl (1500 mg orally with 90 mL of water)
Trial: 23982845
Drug: Ocriplasmin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin (125 μg)
Trial: 23982845
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ocriplasmin injection)
Trial: 23983212
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir 600 mg twice daily for up to 10 days
Trial: 23983245
Drug: Multielectrode radiofrequency
RxNorm normalized name: SUPER-VIAL HYPERLYTE MULTIELECTROLYTE CONC INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multielectrode radiofrequency (MER) system with procedural changes (therapeutic vitamin K antagonist and heparin, submerged loading of the catheter, deactivation of either distal or proximal electrode)
Trial: 23983684
Drug: 0.7 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 μg/kg dexmedetomidine
Trial: 23983823
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy plus STn-KLH vaccine
Trial: 23983823
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy plus STn-KLH vaccine with median or greater antibody response
Trial: 23984046
Drug: Leucine +
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine + phenylalanine (1 mmol/kg fat free body mass each) + 25 g glucose
Trial: 23984082
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg mifepristone daily for 3 months
Trial: 23984082
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg mifepristone daily for 3 months
Trial: 23984185
Drug: 250 μCi
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μCi of (131)I/mL thyroid tissue, corrected by 24-RAIU values (Group 1)
Trial: 23984185
Drug: 200 μCi
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μCi of (131)I/mL/24-RAIU (Group 2, historical control)
Trial: 23985703
Drug: Benidipine combined
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine combined with β-blocker (BB)
Trial: 23985703
Drug: Benidipine combined
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine combined with thiazide diuretic (TD)
Trial: 23985703
Drug: Benidipine combined
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine combined with angiotensin receptor blocker (ARB)
Trial: 23986161
Drug: Calcipotriene plus
RxNorm normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene plus betamethasone dipropionate topical suspension
Trial: 23986162
Drug: Apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 20 mg BID for 12 weeks
Trial: 23988361
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with 6 months of anticoagulation and 24 months of compression stockings
Trial: 23989950
Drug: Pazopanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (800 mg daily continuously with a 28-day cycle)
Trial: 23991111
Drug: Interleukin 1
RxNorm normalized name: Interleukin 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin 1 receptor antagonist (IL-1RA)
Trial: 23993936
Drug: Ondansetron administration
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron administration
Trial: 23993936
Drug: Volume of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume of intravenous fluids administered
Trial: 23994660
Drug: Sertraline 50mg
RxNorm normalized name: sertraline 50 MG
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline 50mg to 200mg/day
Trial: 23999023
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of modifiable vascular risk factors and secondary prevention of stroke recurrence
Trial: 24001117
Drug: Using at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using at least 1 other abortive medication with triptan
Trial: 24002496
Drug: Quizartinib administered
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib administered orally at escalating doses of 12 to 450 mg/day
Trial: 24002500
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg orally on days 1 through 21 every 28 days until disease progression or intolerance
Trial: 24004118
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening in the PanCan cohort
Trial: 24004118
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening in the BCCA cohort
Trial: 24004540
Drug: Twice-daily Ropinirole
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily Ropinirole prolonged release (RPR)
Trial: 24004540
Drug: Once-daily Ropinirole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily Ropinirole prolonged release (RPR)
Trial: 24004540
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (once-daily and twice-daily RPR)
Trial: 24004642
Drug: DAPT discontinuation
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT discontinuation
Trial: 24004667
Drug: Bortezomib, dexamethasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib, dexamethasone, and rituximab (BDR) combination therapy
Trial: 24005614
Drug: Sorafenib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib at a dose of 800 mg daily
Trial: 24006858
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at a dosage of 40 ppm
Trial: 24007746
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m², Cyclophosphamide 600 mg/m², Trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15 during chemotherapy, followed by Trastuzumab 6 mg/kg every three weeks for 1 year.
Trial: 24007819
Drug: Bevacizumab (7.5mg/kg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5mg/kg, day 1), weekly paclitaxel (80 mg/m(2) days 1, 8, 15), and carboplatin (AUC6, day 1) intravenously q3w for 6-8 cycles, followed by single-agent bevacizumab for 1 year.
Trial: 24008739
Drug: PCV13 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (1 dose)
Trial: 24013510
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and capecitabine (first-line combination treatment)
Trial: 24013904
Drug: Capecitabine 650
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 650 mg/m(2) twice daily and everolimus 5 mg twice daily
Trial: 24014245
Drug: Carfilzomib, lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at maximum planned dose (MPD)
Trial: 24014245
Drug: Carfilzomib, lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in bortezomib-refractory patients
Trial: 24014245
Drug: Carfilzomib, lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in lenalidomide-refractory patients
Trial: 24014245
Drug: Carfilzomib, lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at MPD
Trial: 24015953
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of dexamethasone in 2 ml saline (treatment group)
Trial: 24019544
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg plus bortezomib 1.3 mg/m(2) (MTD) in the escalation phase
Trial: 24022390
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg daily in three divided doses (control)
Trial: 24023466
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (2 g/day)
Trial: 24023652
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion test
Trial: 24023652
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion test in patients with good hypoglycaemia awareness
Trial: 24023652
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion test in patients with poor hypoglycaemia awareness
Trial: 24024534
Drug: Quetiapine (flexibly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (flexibly dosed at 400-800 mg/day, with options to reduce to 200 mg/day based on tolerability)
Trial: 24025627
Drug: Control solutions
RxNorm normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solutions (carrot juice, NaCl, caffeine, urea)
Trial: 24025631
Drug: Potassium excretion
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium excretion measurement
Trial: 24025631
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of potassium excretion by race
Trial: 24025631
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of potassium excretion by education level
Trial: 24025631
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of potassium excretion by income level
Trial: 24028306
Drug: Intervention: Intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs (diuretic, ACE inhibitors, β-adrenergic blocking agent, calcium channel blocking agent) if BP >130/80 mmHg.
Trial: 24028306
Drug: Intervention: Intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs.
Trial: 24028677
Drug: Omalizumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (75 or 150 mg in a pre-filled syringe) at 2 or 4 week intervals for 24 weeks
Trial: 24028749
Drug: Etonogestrel contraceptive
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etonogestrel contraceptive implant placed within 15 min of mifepristone administration
Trial: 24030098
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg daily on days 1-21 every 28 days until progressive disease or intolerability
Trial: 24030879
Drug: IPTp with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPTp with sulfadoxine/pyrimethamine (SP) given twice during pregnancy
Trial: 24030918
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 30 or 40 mg/m² intravenously on day 1; dexamethasone 40 mg orally on days 1-4; lenalidomide 25 mg orally on days 1-21, administered every 28 days
Trial: 24030918
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with lenalidomide
Trial: 24030928
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) with protease inhibitors (PIs)
Trial: 24032456
Drug: Ofatumumab 300
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 300 mg IV on Day 1, followed by seven weekly IV infusions of 1000 mg.
Trial: 24034562
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion radiotherapy combined with weekly gemcitabine and adjuvant gemcitabine
Trial: 24035405
Drug: Tremelimumab 15
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 15 mg/kg intravenously once every 90 days until progressive disease or severe toxicity
Trial: 24037550
Drug: Herpes zoster
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herpes zoster vaccine (Zostavax)
Trial: 24037866
Drug: Community-directed treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-directed treatment (ComDT) added to health facility (HF) approach
Trial: 24037867
Drug: Non-recommended antimalarials
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-recommended antimalarials
Trial: 24038364
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine/pyrimethamine (IPTi-SP)
Trial: 24045608
Drug: Intravenous amantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amantadine sulfate 200 mg